Lab
Bioreference Health, LLC
Bioreference Health, LLC was paid $8.87M by Medicaid between Jan 2018 and Dec 2024, across 171 billing codes. Its largest line is 87591, Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe — 7.6% of everything it billed.
33Billing provider infoBIOREFERENCE HEALTH, LLC
HOUSTON, TX 77054
HOUSTON, TX 77054
33aNPI1316322035assigned 07/23/2015
33bProvider typeClinical Medical Laboratory
28Total paid$8.87M
24GClaims1,011,391
24DCodes billed171
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Texas
Rank by total paid#20 of 436
Median peer was paid$17K
This provider vs. median514×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 26,231 | $340K | |
| 2019 | 23,841 | $272K | |
| 2020 | 79,019 | $464K | |
| 2021 | 208,031 | $1.51M | |
| 2022 | 250,542 | $2.33M | |
| 2023 | 261,076 | $2.39M | |
| 2024incomplete | 162,651 | $1.56M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 7.6% | 40,256 | 39,072 | $673K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 7.6% | 40,108 | 39,074 | $672K |
| 81507 | 6.4% | 2,653 | 2,499 | $567K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 5.8% | 30,189 | 29,368 | $515K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 5.8% | 3,042 | 2,906 | $514K |
| 80081 | 5.7% | 12,666 | 12,458 | $503K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 5.3% | 38,032 | 37,516 | $468K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 4.4% | 41,744 | 40,801 | $388K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 4.3% | 14,133 | 13,549 | $379K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 3.0% | 15,518 | 15,241 | $263K |
| 87512 | 2.9% | 14,432 | 14,133 | $261K | |
| 87799 | 2.9% | 12,291 | 11,831 | $257K |
159 more codes
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 2.9% | 14,368 | $255K |
| 87481 | 2.5% | 14,148 | $218K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.8% | 43,337 | $160K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 52,585 | $143K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.6% | 24,763 | $141K |
| 86803 | 1.4% | 23,278 | $124K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.4% | 2,385 | $120K |
| 87563 | 1.3% | 8,206 | $118K | |
| 87653 | 1.2% | 6,645 | $104K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.1% | 2,080 | $102K |
| 81329 | <1% | 1,846 | $75K | |
| 87529 | <1% | 4,617 | $74K | |
| 87340 | <1% | 17,930 | $70K | |
| 80053 | Comprehensive metabolic panel | <1% | 26,902 | $70K |
| 87077 | <1% | 20,611 | $69K | |
| 86592 | <1% | 36,823 | $65K | |
| 80050 | General health panel | <1% | 2,830 | $63K |
| 88141 | <1% | 6,000 | $61K | |
| 87186 | <1% | 16,641 | $61K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 6,606 | $59K |
| 84702 | <1% | 7,644 | $57K | |
| 82105 | <1% | 8,222 | $56K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 16,494 | $56K |
| 87088 | <1% | 15,778 | $56K | |
| 87070 | <1% | 13,990 | $54K | |
| 83021 | <1% | 5,528 | $53K | |
| 80055 | <1% | 3,750 | $49K | |
| 86762 | <1% | 7,569 | $49K | |
| 80061 | Lipid panel | <1% | 13,863 | $41K |
| 86696 | <1% | 5,128 | $40K | |
| 82950 | <1% | 18,539 | $38K | |
| 86850 | <1% | 9,501 | $37K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 2,639 | $33K |
| 82951 | <1% | 5,650 | $32K | |
| 82728 | <1% | 7,158 | $31K | |
| 86787 | <1% | 5,728 | $29K | |
| 88344 | <1% | 281 | $26K | |
| 84144 | <1% | 2,743 | $23K | |
| 87522 | Neg quan hep c or qual rna | <1% | 1,053 | $21K |
| 82607 | <1% | 4,555 | $21K | |
| 88142 | <1% | 2,817 | $21K | |
| 82670 | <1% | 2,123 | $21K | |
| 86695 | <1% | 4,069 | $21K | |
| 86780 | <1% | 2,791 | $19K | |
| 84439 | <1% | 6,877 | $19K | |
| 84403 | <1% | 2,141 | $18K | |
| 84481 | <1% | 2,991 | $16K | |
| 82746 | <1% | 3,403 | $15K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,105 | $15K |
| 86235 | <1% | 494 | $13K | |
| 83550 | <1% | 5,089 | $13K | |
| 83001 | <1% | 2,354 | $12K | |
| 84146 | <1% | 1,926 | $12K | |
| 83540 | <1% | 5,920 | $12K | |
| 80074 | <1% | 1,464 | $12K | |
| 86900 | <1% | 8,445 | $11K | |
| 86901 | <1% | 8,394 | $11K | |
| 85027 | <1% | 3,837 | $11K | |
| 81001 | <1% | 9,075 | $10K | |
| 86376 | <1% | 2,195 | $9K | |
| 81243 | <1% | 1,022 | $9K | |
| 82952 | <1% | 4,834 | $9K | |
| 84550 | <1% | 4,968 | $8K | |
| 86706 | <1% | 1,984 | $8K | |
| 83002 | <1% | 1,442 | $7K | |
| 84270 | <1% | 1,012 | $7K | |
| 86704 | <1% | 1,655 | $6K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 110,170 | $6K |
| 86800 | <1% | 1,309 | $5K | |
| 82947 | <1% | 2,501 | $5K | |
| 84156 | <1% | 3,284 | $5K | |
| 82570 | <1% | 2,735 | $4K | |
| 85660 | <1% | 2,264 | $4K | |
| 83615 | <1% | 1,565 | $4K | |
| 87184 | <1% | 1,186 | $3K | |
| 82627 | <1% | 424 | $3K | |
| 86038 | <1% | 793 | $3K | |
| 86141 | <1% | 838 | $3K | |
| 85651 | <1% | 2,963 | $3K | |
| 82679 | <1% | 494 | $2K | |
| 82677 | <1% | 450 | $2K | |
| 84480 | <1% | 1,053 | $2K | |
| 86140 | <1% | 1,861 | $2K | |
| 86870 | <1% | 358 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 70 | $2K |
| 82575 | <1% | 538 | $2K | |
| 86015 | <1% | 52 | $2K | |
| 83498 | <1% | 199 | $2K | |
| 86225 | <1% | 301 | $2K | |
| 86160 | <1% | 160 | $1K | |
| 82040 | <1% | 1,278 | $1K | |
| 84436 | <1% | 1,421 | $1K | |
| 85730 | <1% | 630 | $1K | |
| 85610 | <1% | 912 | $1K | |
| 83695 | <1% | 736 | $1K | |
| 86200 | <1% | 215 | $1K | |
| 85018 | <1% | 1,634 | $1K | |
| 85014 | <1% | 1,621 | $1K | |
| 86147 | <1% | 59 | $1K | |
| 99199 | Unlisted special service, procedure or report | <1% | 632 | $1K |
| 86593 | <1% | 814 | $1K | |
| 86003 | <1% | 48 | $1K | |
| 84450 | <1% | 946 | $1K | |
| 83970 | <1% | 154 | $1K | |
| 83525 | <1% | 395 | $1K | |
| 82565 | <1% | 700 | $1K | |
| 82239 | <1% | 179 | $982.42 | |
| 86431 | <1% | 544 | $971.21 | |
| 81050 | <1% | 793 | $971.00 | |
| 84460 | <1% | 846 | $952.74 | |
| 84520 | <1% | 773 | $937.59 | |
| 84479 | <1% | 964 | $906.65 | |
| 82550 | <1% | 383 | $892.32 | |
| 87075 | <1% | 215 | $809.94 | |
| 80076 | <1% | 199 | $746.98 | |
| 82465 | <1% | 548 | $741.78 | |
| 80051 | <1% | 287 | $726.98 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 784 | $710.22 |
| 86304 | <1% | 129 | $696.77 | |
| 86039 | <1% | 145 | $680.75 | |
| 82043 | <1% | 571 | $664.15 | |
| 86886 | <1% | 358 | $642.95 | |
| 82977 | <1% | 334 | $619.35 | |
| 84075 | <1% | 705 | $580.79 | |
| 82247 | <1% | 704 | $549.86 | |
| 84432 | <1% | 87 | $525.58 | |
| 82671 | <1% | 81 | $505.77 | |
| 86480 | <1% | 24 | $472.96 | |
| 86777 | <1% | 97 | $466.10 | |
| 82785 | <1% | 102 | $447.13 | |
| 87205 | <1% | 216 | $414.12 | |
| 84155 | <1% | 704 | $399.24 | |
| 84153 | <1% | 427 | $374.13 | |
| 83735 | <1% | 138 | $356.12 | |
| 82310 | <1% | 235 | $347.79 | |
| 86709 | <1% | 160 | $336.08 | |
| 84100 | <1% | 174 | $319.96 | |
| 87480 | <1% | 48 | $295.81 | |
| 87660 | <1% | 46 | $264.85 | |
| 86747 | <1% | 14 | $262.73 | |
| 86778 | <1% | 44 | $242.70 | |
| 83690 | <1% | 98 | $216.22 | |
| 86146 | <1% | 15 | $211.47 | |
| 81511 | <1% | 2,713 | $204.00 | |
| 82542 | <1% | 18 | $201.74 | |
| 80069 | <1% | 67 | $163.73 | |
| 86705 | <1% | 97 | $159.85 | |
| 87510 | <1% | 42 | $84.20 | |
| 82533 | <1% | 17 | $80.19 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 56 | $53.92 |
| 84478 | <1% | 13 | $50.18 | |
| 84425 | <1% | 12 | $49.60 | |
| 82248 | <1% | 26 | $39.39 | |
| 82150 | <1% | 13 | $32.87 | |
| 85007 | <1% | 17 | $14.04 | |
| 81508 | 0% | 318 | $0.00 | |
| 83701 | 0% | 12 | $0.00 | |
| 81422 | 0% | 65 | $0.00 | |
| 81443 | 0% | 66 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCHMID, MICHAEL (SVP, CHIEF FINANCIAL OFFICER)
Parent organizationBIOREFERENCE HEALTH, LLC
| Provider | Location | Paid |
|---|---|---|
| Bioreference Health, LLC | Elmwood Park, NJ | $620.07M |
| Florida Clinical Laboratory, INC | Melbourne, FL | $549K |
| Bioreference Health, LLC | Mineola, NY | $175K |
| Bioreference Health, LLC | Houston, TX | $117K |
| Bioreference Health, LLC | Burbank, CA | $25K |
| Bioreference Health, LLC | Gaithersburg, MD | $8K |
| Bioreference Health, LLC | Hackensack, NJ | $22.86 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.